Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring (“ODM”), has today announced the launch this week of its revolutionary concept in advanced haemodynamic monitoring, the TrueVue™ system.
The TrueVue™ system comprises three distinct best-in-class advanced haemodynamic monitoring technologies on a single platform (the CardioQ-ODM+):
– TrueVue™ Doppler: high-end ODM technology providing beat-to-beat imaging of cardiac output for monitoring sedated patients and easy calibration/recalibration of arterial pressure cardiac output
– TrueVue™ Impedance: non-invasive, high definition impedance cardiography for monitoring awake patients, both mobile and immobile
– TrueVue™ Loops: unique real-time biomarkers for early detection of hypo- and hyper-volaemia, hypo- and hyper-tension and real-time display of responses to treatment
The TrueVue™ system is being featured at Deltex’s booth at Anesthesiology 2017, the annual meeting of the American Society of Anesthesiologists in Boston, MA. This is the largest anaesthesia conference in the USA and is attended by large numbers of international delegates as well as thousands of doctors from across the USA.
Use of TrueVue™ Impedance in the USA is subject to FDA approval: the submission (510K) has been submitted and not yet granted.
Ewan Phillips, Deltex Medical Group Plc Chief Executive, commented: “The launch of the TrueVue™ system on the CardioQ-ODM+ platform is an exciting development for the Company. It means we will now be marketing the world’s first haemodynamic monitoring system which can be used across the whole patient pathway from awake, mobile outpatients of all ages through to sedated, critical care patients. The TrueVue™ system can be used by trainee staff, in non-critical situations, through to experienced specialists. It will also broaden the Company’s addressable market and positions us to supply hospitals with all their haemodynamic monitoring requirements on a single platform.”
